Pfizer's Xalkori, Kyowa Hakko Kirin's Poteligeo And Others Receive Chuikyo Pricing
This article was originally published in PharmAsia News
Kyowa Hakko Kirin's Poteligeo cleared for first global market launch, earning a 10% premium for added-value benefits.
You may also be interested in...
Daiichi Sankyo's Edoxaban Enters Its First Market; Eisai "Very Pleased" With Eribulin Japanese Price Listing
TOKYO - Drugmakers introduced a number of new products in Japan this week, including the first launch globally of Daiichi Sankyo Co. Ltd.'s oral factor Xa inhibitor edoxaban, following the release of National Health Insurance price listings
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.